The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

Danish pharmaceutical giant Novo Nordisk sees a significant increase in profits and sales despite production constraints.

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

4️⃣ Drug warning: Compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, have been associated with ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The ...

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...